America Stem Cell, Inc. Receives Orphan Drug Designation for ASC-101; Novel Enabling Technology to Enhance Stem Cell Treatments for Cancer Patients

April 2011
Biomedical Market Newsletter;4/30/2011, p31
The article reports that America Stem Cell Inc. has received Orphan Drug Designation to its ASC-101from the U.S. Food and Drug Administration (FDA). It mentions that the drug aims to improve homing to bone marrow in patients receiving hematopoietic stem cell transplantation. It affirms that the status depicts the importance of the new novel treatment approach in improving patient outcomes.


Related Articles

  • Recommendations on hematopoietic stem cell transplantation for inherited bone marrow failure syndromes. Peffault de Latour, R; Peters, C; Gibson, B; Strahm, B; Lankester, A; de Heredia, C D; Longoni, D; Fioredda, F; Locatelli, F; Yaniv, I; Wachowiak, J; Donadieu, J; Lawitschka, A; Bierings, M; Wlodarski, M; Corbacioglu, S; Bonanomi, S; Samarasinghe, S; Leblanc, T; Dufour, C // Bone Marrow Transplantation;Sep2015, Vol. 50 Issue 9, p1168 

    Allogeneic hematopoietic stem cell transplantation (HSCT) offers the potential to cure patients with an inherited bone marrow failure syndrome (IBMFS). However, the procedure involves the risk of treatment-related mortality and may be associated with significant early and late morbidity. For...

  • Improving Safety of Preemptive Therapy with Oral Valganciclovir for Cytomegalovirus Infection after Allogeneic Hematopoietic Stem Cell Transplantation. Barkam, Corinna; Kamal, Haytham; Dammann, Elke; Diedrich, Helmut; Buchholz, Stefanie; Eder, Matthias; Krauter, Jürgen; Ganser, Arnold; Stadler, Michael // Bone Marrow Research;2012, p1 

    Valganciclovir (VGC), an oral prodrug of ganciclovir (GCV), has been shown to clear cytomegalovirus (CMV) viremia in preemptive treatment of patients after allogeneic hematopoietic stem cell transplantation (alloHSCT), apparently without significant toxicity. Since VGC obviates hospitalization,...

  • Noninvasive mechanical ventilation as early intervention in hematopoietic SCT: protective, therapeutic or futile? The lungs may have the correct answer. Esquinas, A; Pieter, D // Bone Marrow Transplantation;Mar2013, Vol. 48 Issue 3, p463 

    A letter to the editor is presented in response to the article by Wermke and colleagues on the impact of early noninvasive mechanical ventilation (NIV) in hematopoietic SCT of immunocompromised patients, that was published online in the September 3, 2012 issue.

  • New therapeutic agents marketed in the first half of 2006. Hussar, Daniel A. // Pharmacy Today;Dec2006, Vol. 12 Issue 12, p48 

    The article reports on the 14 new therapeutic agents marketed from January to June 2006 in the U.S. Twelve of them are classified as new molecular entities and 2 as biological agents. Six of the agents are used to treat conditions that occur infrequently and designated as orphan drugs....

  • Take-Home Message.  // Ophthalmology Times;10/15/2003, Vol. 28 Issue 20, p26 

    Discusses the grant given to Orphan Drug designation by the U.S. Food and Drug Administration for agalsidase beta, an enzyme replacement therapy for the treatment of Fabry's disease.

  • Gentium Announces NDA Submission for Defibrotide.  // Worldwide Biotech;Aug2011, Vol. 23 Issue 8, p2 

    The article reports on a new drug application (NDA) submitted by Gentium SpA to the U.S. Food and Drug Administration (FDA) for Defibrotide for the treatment of hepatic veno-occlusive disease (VOD) in patients undergoing hematopoietic stem-cell transplantation (HSCT). The drug has allegedly been...

  • Diabetic Stem-Cell �Mobilopathy�. DiPersio, John F. // New England Journal of Medicine;12/29/2011, Vol. 365 Issue 26, p2536 

    The article discusses hematopoietic stem-cell (HSC) transplantation as the primary curative treatment for hematologic cancer patients. It says that the U.S. Food and Drug Administration approved the granulocyte colony-stimulating factor (G-CSF) and granulocyte macrophage colony-stimulating...

  • FDA approves first stem-cell therapy. Traynor, Kate // American Journal of Health-System Pharmacy;12/15/2011, Vol. 68 Issue 24, p2316 

    The article reports that the FDA has approved New York Blood Center's allogeneic cord-blood product, Hemacord, the first U.S.-licensed hematopoietic progenitor cell therapy. It also discusses a successful transplantation procedure using Hemacord which is indicated for patients with inherited,...

  • MDS: THERE'S LIGHT AT THE END OF THE TUNNEL. Hitchens, Kathy // Drug Topics;5/22/2006, Vol. 150 Issue 10, pHSE14 

    The article discusses the advancement in the treatment of myelodysplastic syndromes (MDS), a bone marrow and blood elements affecting disease. Several drugs have been approved by the U.S. Food and Drug Administration used to treat MDS which include azacitidine, lenalidomide, decitabine, and the...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics